meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
versus all
vs immune chekpoint inhibitors
vs others immune checkpoint inhibitors
vs brentuximab vedotin
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
ECOG 0
ECOG 1
Gender, female
Gender, male
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DOR
objective responses (ORR)
progression or deaths (PFS)
AE leading to death (grade 5)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Abdominal pain TRAE (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Eczema TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Pneumonia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Urticaria TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
DOR
R/R cHL - second line or more (L2)
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
versus brentuximab vedotin
pembrolizumab alone vs. brentuximab vedotin
1
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open